IGF1 and neoplasm: Among the 65 patients (60.7%) with controlled IGF-I and tumour status (IGF-I < ULN and tumour not visible or without changes), 13 (20.0%) and 34 (52.3%) presented severe and moderate symptoms respectively according to their phPASQ (32.3 % and 53.8% respectively according to their paPASQ).